Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab vedotin in MET amplified non-squamous NSCLC
NCT05513703Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
A Phase 2 trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc.. Started Nov 2022; status: terminated.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05513703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513703.